A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively ...
Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...
Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...
Cabometyx is already approved as a second-line treatment for HCC in people who have previously received Nexavar, along with first- and second-line approvals for RCC, with sales reaching $720 ...
Zacks.com on MSN1d
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...
Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...
Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a second line therapy option for patients previously treated with Bayer’s Nexavar.
Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback